Clinical Trial

PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update

TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for…

1 year ago

Yunu Integration to Florence Improves Imaging Accuracy and Workflow Efficiency

Partnership extends capability for trial imaging integration to Florence Healthcare's 18,000 activated clinical trial sites.ATLANTA, GA / ACCESSWIRE / November…

1 year ago

FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023

TORONTO, ON / ACCESSWIRE / November 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

1 year ago

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment…

1 year ago

NanoViricides Has Filed its Quarterly Report – NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed…

1 year ago

PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules

Filament Health and PharmAla Biotech also completed shipments to a number of Australian clientsVANCOUVER, British Columbia, Nov. 15, 2023 (GLOBE…

1 year ago

Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes

– Randomized, placebo-controlled trial to assess 16-week treatment with CT-868 in participants with overweight or obesity with type 1 diabetes…

1 year ago

Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto,…

1 year ago

MindLeaf Technologies Spins Off Its Life Sciences Division as a Separate Entity, CliniLink Health

LOWELL, Mass.--(BUSINESS WIRE)--To fill the growing need for clinical trials, MindLeaf Technologies developed a data management platform to help organizations…

1 year ago